AbCellera Biologics Inc. - Common Shares (NQ:ABCL)

13.56 -0.22 (-1.60%)

Delayed Quote Updated: 11:59 AM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about AbCellera Biologics Inc. - Common Shares

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

AbCellera to Report Third Quarter 2026 Financial Results on November 9, 2026

October 01, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Presentation of Phase 2 Data for ABCL635 at the IMS World Congress on Menopause 2026

September 16, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at the Cantor Global Healthcare Conference on September 9, 2026

September 02, 2026

From AbCellera Biologics Inc.

Via Business Wire

Most AI Drug Discovery Reads the Genetic Code. The Next Wave Is Learning to Read What the Code Actually Does.

August 19, 2026

News Provided by USA News Group on behalf of MindWalk Holdings Corp.

From USA News Group

Via GlobeNewswire

AbCellera Biologics (NASDAQ:ABCL) Misses Q2 Estimates, Falls Short on Revenue and EPS ↗

August 05, 2026

Via Chartmill

AbCellera Announces Pricing of Oversubscribed $200 Million Public Offering of Common Shares and Pre-Funded Warrants

August 13, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera (ABCL) Q2 2026 Earnings Call Transcript ↗

August 12, 2026

Lead program ABCL635 Phase 2 enrollment complete with data expected in August.

Via The Motley Fool

Topics Earnings Intellectual Property

AbCellera Announces Proposed Public Offering of Common Stock and Pre-Funded Warrants

August 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

Here are the top movers in Monday's session. ↗

August 10, 2026

Via Chartmill

There are notable gap-ups and gap-downs in today's session. ↗

August 10, 2026

Via Chartmill

AI Found an Influenza Target That Survives Viral Mutation

August 10, 2026

Issued on behalf of MindWalk Holdings Corp. (Nasdaq: HYFT)

From Equity Insider

Via GlobeNewswire

AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial ↗

August 10, 2026

AbCellera Biologics (NASDAQ:ABCL) reported top-line four-week results from a Phase II trial of ABCL-635, an investigational non-hormonal treatment for moderate to severe vasomotor symptoms, or hot...

Via MarketBeat

AbCellera Announces Positive Top-Line Phase 2 Clinical Trial Results for ABCL635, Demonstrating Significant Reduction in Frequency and Severity of Vasomotor Symptoms and a Favorable Tolerability Profile

August 10, 2026

From AbCellera Biologics Inc.

Via Business Wire

12 Health Care Stocks Moving In Friday's After-Market Session ↗

August 07, 2026

Gainers AbCellera Biologics (NASDAQ:ABCL) shares increased by 8.2% to $7.5 during Friday's after-market session. The company's market cap stands at $1.9 billion. As per the news, the Q2 earnings report...

Via Benzinga

Get insights into the top gainers and losers of Friday's after-hours session. ↗

August 07, 2026

Via Chartmill

AbCellera to Announce Top-Line Results from the Phase 2 Trial of ABCL635 for the Treatment of Moderate-to-Severe VMS Due to Menopause on Monday, August 10, 2026

August 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics Q2 Earnings Call Highlights ↗

August 05, 2026

AbCellera Biologics (NASDAQ:ABCL) said it expects to report top-line data “very soon” from its Phase I study of ABCL635, an antibody being evaluated for moderate-to-severe vasomotor symptoms, or hot...

Via MarketBeat

Topics Earnings

AbCellera Reports Q2 2026 Business Results

August 05, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Announces Collaboration with Vertex to Discover Multispecific T-Cell Engagers for Autoimmune Diseases and Other Conditions

July 29, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Report Second Quarter 2026 Financial Results on August 5, 2026

July 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Lynn Seely to its Board of Directors

July 06, 2026

From AbCellera Biologics Inc.

Via Business Wire

Jazz Pharmaceuticals and AbCellera Announce Collaboration to Discover Next-Generation T-cell Engaging Multispecific Antibodies

June 17, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Appoints Dr. Victor Sandor to its Board of Directors

June 05, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera Biologics Bets on Hot Flash Antibody as Pipeline Pivot Gains Steam ↗

June 04, 2026

AbCellera Biologics (NASDAQ:ABCL) is emphasizing its transition from a partner-based antibody discovery business to a proprietary drug development company, Chief Financial Officer Andrew Booth said...

Via MarketBeat

AbCellera Biologics Q1 Earnings Call Highlights ↗

May 11, 2026

AbCellera Biologics (NASDAQ:ABCL) said its first quarter of 2026 was marked by progress in its internal drug pipeline, including interim Phase 1 data for its lead program, ABCL635, and continued...

Via MarketBeat

Topics Earnings

AbCellera (ABCL) Q1 2026 Earnings Transcript ↗

May 11, 2026

AbCellera (ABCL) Q1 2026 Earnings Transcript

Via The Motley Fool

Topics Intellectual Property

Stay updated with the stocks that are on the move in today's after-hours session. ↗

May 11, 2026

Via Chartmill

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

May 11, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

May 07, 2026

From AbCellera Biologics Inc.

Via Business Wire

AbCellera to Highlight Phase 1 Clinical Data for ABCL635 During Upcoming First Quarter 2026 Earnings Call

April 20, 2026

From AbCellera Biologics Inc.

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.